The role of nuclear receptors in the kidney in obesity and metabolic syndrome

Genes and Nutrition

Volumn 7, Issue 4, 2012, Pages 483-498

  Tovar Palacio, Claudia ^a   Torres, Nimbe ^a   Diaz Villaseñor, Andrea ^a   Tovar, Armando R ^a  

^a National Medical Science and Nutrition Institute   (Mexico)

Author keywords

Kidney; Metabolic syndrome; Nuclear receptors; Obesity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CELL NUCLEUS RECEPTOR; FARNESOID X RECEPTOR; FARNESOID X RECEPTOR ALPHA; FARNESOID X RECEPTOR BETA; FENOFIBRATE; FIBRIC ACID DERIVATIVE; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; OBETICHOLIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PREGNANE X RECEPTOR; STEROID RECEPTOR; UNCLASSIFIED DRUG; XENOBIOTIC RECEPTOR;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; HUMAN; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY INJURY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; RISK FACTOR; TRANSCRIPTION REGULATION;

EID: 84872181606     PISSN: 15558932     EISSN: 18653499     Source Type: Journal    
DOI: 10.1007/s12263-012-0295-5     Document Type: Article

References (127)

1. Ambroziak K, Kuteykin-Teplyakov K, Luna-Tortos C, Al-Falah M, Fedrowitz M, Loscher W (2010) Exposure to antiepileptic drugs does not alter the functionality of P-glycoprotein in brain capillary endothelial and kidney cell lines. Eur J Pharmacol 628(1-3):57-66. doi:10.1016/j.ejphar.2009.11.051
2. Arici M, Chana R, Lewington A, Brown J, Brunskill NJ (2003) Stimulation of proximal tubular cell apoptosis by albumin-bound fatty acids mediated by peroxisome proliferator activated receptor-gamma. J Am Soc Nephrol 14(1):17-27 (Pubitemid 36026293)
3. Balakumar P, Rose M, Ganti SS, Krishan P, Singh M (2007) PPAR dual agonists: Are they opening Pandora's Box? Pharmacol Res 56(2):91-98. doi:10.1016/j.phrs.2007.03.002 (Pubitemid 47304493)
4. Benoit G, Cooney A, Giguere V, Ingraham H, Lazar M, Muscat G, Perlmann T, Renaud JP, Schwabe J, Sladek F, Tsai MJ, Laudet V (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol Rev 58(4):798-836. doi:10.1124/ pr.58.4.10 (Pubitemid 44833747)
5. Berfield AK, Chait A, Oram JF, Zager RA, Johnson AC, Abrass CK (2006) IGF-1 induces rat glomerular mesangial cells to accumulate triglyceride. Am J Physiol Renal Physiol 290(1):F138-F147. doi:10.1152/ajprenal.00054.2005
6. Berger JP, Akiyama TE, Meinke PT (2005) PPARs: Therapeutic targets for metabolic disease. Trends Pharmacol Sci 26(5):244-251. doi:10.1016/j.tips.2005. 03.003 (Pubitemid 40603072)
7. Blouin RA, Farrell GC, Ioannides C, Renton K, Watlington CO (1999) Impact of diseases on detoxication. J Biochem Mol Toxicol 13(3-4):215-218 (Pubitemid 129705394)
8. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11(2):183-190. doi:10.1038/nm1166 (Pubitemid 40321354)
9. Chan W, Wang M, Martin RJ, Trachtman H, Hisano S, Chan JC (2001) mRNA expression for insulin-like growth factor 1, receptors of growth hormone and IGF-1 and transforming growth factor-beta in the kidney and liver of Zucker rats. Nutr Res 21(7):1015-1023 (Pubitemid 32641713)
10. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ (2001) Nuclear receptors and lipid physiology: Opening the X-files. Science 294(5548):1866-1870. doi:10.1126/science.294.5548.1866 (Pubitemid 33101573)
11. Chen M, Xu D, Hu XL, Wang H (2008) Effects of liver fibrosis on verapamil pharmacokinetics in rats. Clin Exp Pharmacol Physiol 35(3):287-294. doi:10.1111/j.1440-1681.2007.04826.x (Pubitemid 351257881)
12. Cheng X, Klaassen CD (2006) Regulation of mRNA expression of xenobiotic transporters by the pregnane x receptor in mouse liver, kidney, and intestine. Drug Metab Dispos 34(11):1863-1867. doi:10.1124/dmd.106.010520 (Pubitemid 44771714)
13. Cheng CF, Chen HH, Lin H (2010) Role of PPAR alpha and its agonist in renal diseases. PPAR research 2010:345098. doi: 10.1155/2010/345098
14. Cheymol G (2000) Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 39(3):215-231
15. Cortes V, Quezada N, Rigotti A, Maiz A (2005) New heterodimeric nuclear receptors: Key metabolic regulators with relevance in the pathophysiology and therapy of dyslipidemias and diabetes mellitus. Rev Med Chil 133(12):1483-1492 (Pubitemid 43213832)
16. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W (1996) The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384(6604):39-43. doi:10.1038/384039a0
17. Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, Schiffrin EL (2002) PPARalpha activator effects on Ang IIinduced vascular oxidative stress and inflammation. Hypertension 40(6):866-871 (Pubitemid 35434908)
18. Dobrian AD (2006) The complex role of PPARgamma in renal dysfunction in obesity: Managing a Janus-faced receptor. Vascul Pharmacol 45(1):36-45. doi:10.1016/j.vph.2006.01.017 (Pubitemid 43996805)
19. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B (2001) Rat PPARs: Quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142(10):4195-4202 (Pubitemid 32907045)
20. Escriva H, Safi R, Hanni C, Langlois MC, Saumitou-Laprade P, Stehelin D, Capron A, Pierce R, Laudet V (1997) Ligand binding was acquired during evolution of nuclear receptors. Proc Natl Acad Sci USA 94(13):6803-6808 (Pubitemid 27281945)
21. Fiorucci S, Antonelli E, Rizzo G, Renga B, Mencarelli A, Riccardi L, Orlandi S, Pellicciari R, Morelli A (2004) The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127(5):1497-1512 (Pubitemid 39457775)
22. Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, Noonan DJ, Burka LT, McMorris T, Lamph WW, Evans RM, Weinberger C (1995) Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81(5):687-693
23. Francis GA, Fayard E, Picard F, Auwerx J (2003) Nuclear receptors and the control of metabolism. Annu Rev Physiol 65:261-311. doi:10.1146/annurev. physiol.65.092101.142528092101.142528 (Pubitemid 38249155)
24. Fried L, Bernardini J, Piraino B (2001) Charlson comorbidity index as a predictor of outcomes in incident peritoneal dialysis patients. Am J Kidney Dis 37(2):337-342. doi:10.1053/ajkd.2001.21300 (Pubitemid 32116026)
25. Germain P, Staels B, Dacquet C, Spedding M, Laudet V (2006) Overview of nomenclature of nuclear receptors. Pharmacol Rev 58(4):685-704. doi:10.1124/pr.58.4.2 (Pubitemid 44833739)
26. Gilde AJ, van der Lee KA, Willemsen PH, Chinetti G, van der Leij FR, van der Vusse GJ, Staels B, van Bilsen M (2003) Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 92(5):518-524. doi:10.1161/01.RES.0000060700.55247.7C (Pubitemid 36368664)
27. Girnun GD, Domann FE, Moore SA, Robbins ME (2002) Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol Endocrinol 16(12):2793-2801 (Pubitemid 36020658)
28. Goodwin B, Kliewer SA (2002) Nuclear receptors. I. Nuclear receptors and bile acid homeostasis. Am J Physiol Gastrointest Liver Physiol 282(6):G926-931. doi:10.1152/ajpgi.00044.2002 (Pubitemid 34651597)
29. Guan Y, Zhang Y, Davis L, Breyer MD (1997) Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Physiol 273(6 Pt 2):F1013-F1022
30. Guan Y, Zhang Y, Schneider A, Davis L, Breyer RM, Breyer MD (2001) Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature. Am J Physiol Renal Physiol 281(6):F1036-F1046
31. Guo B, Koya D, Isono M, Sugimoto T, Kashiwagi A, Haneda M (2004) Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells. Diabetes 53(1):200-208 (Pubitemid 38044716)
32. Hao CM, Redha R, Morrow J, Breyer MD (2002) Peroxisome proliferator-activated receptor delta activation promotes cell survival following hypertonic stress. J Biol Chem 277(24):21341-21345. doi:10.1074/jbc.M200695200M200695200 (Pubitemid 34952273)
33. Hartman HB, Gardell SJ, Petucci CJ, Wang S, Krueger JA, Evans MJ (2009) Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/-and apoE-/-mice. J Lipid Res 50(6):1090-1100. doi:10.1194/jlr.M800619- JLR200
34. Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE (2001) Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 12(6):1211-1217 (Pubitemid 32472634)
35. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS (2002) A central role for JNK in obesity and insulin resistance. Nature 420(6913):333-336. doi: 10.1038/nature01137 (Pubitemid 35398190)
36. Hou X, Shen YH, Li C, Wang F, Zhang C, Bu P, Zhang Y (2010) PPARalpha agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity. Biochem Biophys Res Commun 394(3):653-659. doi:10.1016/j.bbrc.2010.03. 043
37. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS (2006) Body mass index and risk for end-stage renal disease. Ann Intern Med 144(1):21-28 (Pubitemid 46780716)
38. Iglesias P, Diez JJ (2006) Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur J Endocrinol 154(5):613-621. doi:10.1530/eje.1.02134 (Pubitemid 43810845)
39. Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S (2004) Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 65(5):1870-1876. doi: 10.1111/j.1523-1755.2004.00582.xKID582 (Pubitemid 38591038)
40. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ (1996) An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 383(6602):728-731. doi:10.1038/ 383728a0 (Pubitemid 26360651)
41. Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391(6662):82-86. doi:10.1038/34184 (Pubitemid 28079219)
42. Jiang T, Wang Z, Proctor G, Moskowitz S, Liebman SE, Rogers T, Lucia MS, Li J, Levi M (2005) Diet-induced obesity in C57BL/ 6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1cdependent pathway. J Biol Chem 280(37):32317-32325. doi: 10.1074/jbc.M500801200 (Pubitemid 41361841)
43. Jiang T, Wang XX, Scherzer P, Wilson P, Tallman J, Takahashi H, Li J, Iwahashi M, Sutherland E, Arend L, Levi M (2007) Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes 56(10):2485-2493. doi:10.2337/ db06-1642 (Pubitemid 47523255)
44. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD (2001) Obesity-related glomerulopathy: An emerging epidemic.Kidney Int 59(4):1498-1509. doi:10.1046/j.1523-1755.2001.0590041498.x (Pubitemid 32281241)
45. Kim MK, Ko SH, Baek KH, Ahn YB, Yoon KH, Kang MI, Lee KW, Song KH (2009) Long-term effects of rosiglitazone on the progressive decline in renal function in patients with type 2 diabetes. Korean J Intern Med 24(3):227-232. doi:10.3904/ kjim.2009.24.3.227
46. Kimmelstiel P, Wilson C (1936) Inflammatory lesions in the glomeruli in pyelonephritis in relation to hypertension and renal insufficiency. Am J Pathol 12(1):483-495
47. Kliewer SA (2003) The nuclear pregnane X receptor regulates xenobiotic detoxification. J Nutr 133(7 Suppl):2444S-2447S (Pubitemid 36828852)
48. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, Zetterstrom RH, Perlmann T, Lehmann JM (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92(1):73-82 (Pubitemid 28053299)
49. Kono K, Kamijo Y, Hora K, Takahashi K, Higuchi M, Kiyosawa K, Shigematsu H, Gonzalez FJ, Aoyama T (2009) PPAR{alpha} attenuates the proinflammatory response in activated mesangial cells. Am J Physiol Renal Physiol 296(2):F328-F336. doi: 10.1152/ajprenal.00484.2007
50. Kuipers I, van der Harst P, Kuipers F, van Genne L, Goris M, Lehtonen JY, van Veldhuisen DJ, van Gilst WH, de Boer RA (2010) Activation of liver X receptor-alpha reduces activation of the renal and cardiac renin-angiotensin- aldosterone system. Lab Invest 90(4):630-636. doi:10.1038/labinvest.2010.7
51. Laffitte BA, Joseph SB, Walczak R, Pei L, Wilpitz DC, Collins JL, Tontonoz P (2001) Autoregulation of the human liver X receptor alpha promoter. Mol Cell Biol 21(22):7558-7568. doi:10.1128/ MCB.21.22.7558-7568.2001 (Pubitemid 32988767)
52. Lehrke M, Lazar MA (2005) The many faces of PPARgamma. Cell 123(6):993-999. doi:10.1016/j.cell.2005.11.026
53. Leik CE, Carson NL, Hennan JK, Basso MD, Liu QY, Crandall DL, Nambi P (2007) GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats. Br J Pharmacol 151(4):450-456. doi: 10.1038/sj.bjp.0707241 (Pubitemid 46905003)
54. Lemberger T, Saladin R, Vazquez M, Assimacopoulos F, Staels B, Desvergne B, Wahli W, Auwerx J (1996) Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm. J Biol Chem 271(3): 1764-1769 (Pubitemid 26028664)
55. Letavernier E, Perez J, Joye E, Bellocq A, Fouqueray B, Haymann JP, Heudes D, Wahli W, Desvergne B, Baud L (2005) Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure. J Am Soc Nephrol 16(8):2395-2402. doi:10.1681/ASN.2004090802 (Pubitemid 41725057)
56. Levi M, Wang X, Choudhury D (2011) Nuclear hormone receptors as therapeutic targets. Contrib Nephrol 170:209-216. doi:10.1159/ 000325668
57. Li YT, Swales KE, Thomas GJ, Warner TD, Bishop-Bailey D (2007) Farnesoid 9 receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol 27(12):2606-2611. doi:10.1161/ATVBAHA. 107.152694 (Pubitemid 350158912)
58. Li L, Emmett N, Mann D, Zhao X (2010) Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-kappaB and transforming growth factor-beta1/ Smad3 in diabetic nephropathy. Exp Biol Med (Maywood) 235(3):383-391. doi:10.1258/ebm.2009.009218
59. Liang YJ, Chen SA, Jian JH (2011) Peroxisome proliferator-activated receptor delta downregulates the expression of the receptor for advanced glycation end products and pro-inflammatory cytokines in the kidney of streptozotocin-induced diabetic mice. Eur J Pharm Sci 43(1-2):65-70. doi:10.1016/j.ejps.2011.03.011
60. Lin H, Hou CC, Cheng CF, Chiu TH, Hsu YH, Sue YM, Chen TH, Hou HH, Chao YC, Cheng TH, Chen CH (2007) Peroxisomal proliferator-activated receptor-alpha protects renal tubular cells from doxorubicin-induced apoptosis. Mol Pharmacol 72(5): 1238-1245. doi:10.1124/mol.107.037523 (Pubitemid 350017443)
61. Lonard DM, Lanz RB, O'Malley BW (2007) Nuclear receptor coregulators and human disease. Endocr Rev 28(5):575-587. doi:10.1210/er.2007-0012 (Pubitemid 47236337)
62. Lu TT, Repa JJ, Mangelsdorf DJ (2001) Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism. J Biol Chem 276(41):37735-37738. doi:10.1074/jbc.R100035200
63. Luo Y, Tall AR (2000) Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest 105(4):513-520. doi:10.1172/JCI8573 (Pubitemid 30127252)
64. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB (2001) Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 59(5):1899-1910. doi:10.1046/j.1523-1755.2001. 0590051899.x (Pubitemid 32336806)
65. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B (1999) Identification of a nuclear receptor for bile acids. Science 284(5418): 1362-1365 (Pubitemid 29289663)
66. Matsuyama M, Yoshimura R, Hase T, Uchida J, Tsuchida K, Takemoto Y, Kawahito Y, Sano H, Nakatani T (2005) Expression of peroxisome proliferator-activated receptor-gamma in renal ischemia-reperfusion injury. Transplant Proc 37(4):1684-1685. doi:10.1016/j.transproceed.2005.02.068 (Pubitemid 40790795)
67. McCarthy KJ, Routh RE, Shaw W, Walsh K, Welbourne TC, Johnson JH (2000) Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 58(6):2341-2350. doi:10.1046/j.1523-1755.2000.00418.x
68. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W (2006) International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 58(4):726-741. doi:10.1124/pr.58.4.5 (Pubitemid 44833742)
69. Miki Y, Suzuki T, Tazawa C, Blumberg B, Sasano H (2005) Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues. Mol Cell Endocrinol 231(1-2):75-85. doi:10.1016/j.mce.2004.12.005 (Pubitemid 40248818)
70. Miyazaki-Anzai S, Levi M, Kratzer A, Ting TC, Lewis LB, Miyazaki M (2010) Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/-mice with chronic kidney disease. Circ Res 106(12):1807-1817. doi:10.1161/ CIRCRESAHA.109.212969
71. Moore DD, Kato S, Xie W, Mangelsdorf DJ, Schmidt DR, Xiao R, Kliewer SA (2006) International Union of Pharmacology. LXII. The NR1H and NR1I receptors: Constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. Pharmacol Rev 58(4):742-759. doi:10.1124/ pr.58.4.6 (Pubitemid 44833743)
72. Moorhead JF, Chan MK, El-Nahas M, Varghese Z (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease. Lancet 2(8311):1309-1311 (Pubitemid 13240921)
73. Morello F, de Boer RA, Steffensen KR, Gnecchi M, Chisholm JW, Boomsma F, Anderson LM, Lawn RM, Gustafsson JA, Lopez-Ilasaca M, Pratt RE, Dzau VJ (2005) Liver X receptors alpha and beta regulate renin expression in vivo. J Clin Invest 115(7):1913-1922. doi:10.1172/JCI24594 (Pubitemid 40979731)
74. Nannelli A, Chirulli V, Longo V, Gervasi PG (2008) Expression and induction by rifampicin of CAR-and PXR-regulated CYP2B and CYP3A in liver, kidney and airways of pig. Toxicology 252(1-3):105-112. doi:10.1016/j.tox.2008. 08.004
75. Nicholas SB, Kawano Y, Wakino S, Collins AR, Hsueh WA (2001) Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells. Hypertension 37(2 Part 2): 722-727 (Pubitemid 32199056)
76. Nitta K (2010) Possible link between metabolic syndrome and chronic kidney disease in the development of cardiovascular disease. Cardiol Res Pract 2011. doi:10.4061/2011/963517
77. Okada T, Wada J, Hida K, Eguchi J, Hashimoto I, Baba M, Yasuhara A, Shikata K, Makino H (2006) Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes 55(6):1666-1677. doi:10.2337/db05-1285 (Pubitemid 44324119)
78. Osabe M, Sugatani J, Fukuyama T, Ikushiro S, Ikari A, Miwa M (2008) Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferatoractivated receptor alpha in male rats fed a high-fat and highsucrose diet. Drug Metab Dispos 36(2):294-302. doi:10.1124/ dmd.107.017731 (Pubitemid 351185741)
79. Owen GI, Zelent A (2000) Origins and evolutionary diversification of the nuclear receptor superfamily. Cell Mol Life Sci 57(5):809-827 (Pubitemid 30392037)
80. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, Lehmann JM (1999) Bile acids: Natural ligands for an orphan nuclear receptor. Science 284(5418):1365-1368 (Pubitemid 29289664)
81. Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, Mangelsdorf DJ (1998) Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 93(5):693-704 (Pubitemid 28257577)
82. Portilla D (2003) Energy metabolism and cytotoxicity. Semin Nephrol 23(5):432-438 (Pubitemid 37176688)
83. Pourcet B, Pineda-Torra I, Derudas B, Staels B, Glineur C (2010) SUMOylation of human peroxisome proliferator-activated receptor alpha inhibits its trans-activity through the recruitment of the nuclear corepressor NCoR. J Biol Chem 285(9):5983-5992. doi:10.1074/jbc.M109.078311
84. Praga M (2002) Obesity-a neglected culprit in renal disease. Nephrol Dial Transplant 17(7):1157-1159 (Pubitemid 34812055)
85. Praga M, Morales E (2006) Obesity, proteinuria and progression of renal failure. Curr Opin Nephrol Hypertens 15(5):481-486. doi: 10.1097/01.mnh. 0000242172.06459.7c00041552-200609000-00 003
86. Proctor G, Jiang T, Iwahashi M, Wang Z, Li J, Levi M (2006) Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes 55(9):2502-2509. doi:10.2337/db05-0603 (Pubitemid 44871150)
87. Robinson E, Grieve DJ (2009) Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacol Ther 122(3):246-263. doi:10.1016/ j.pharmthera.2009.03.003
88. Rosen ED, Spiegelman BM (2001) PPARgamma: A nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276(41):37731-37734. doi:10.1074/jbc.R100034200
89. Rosenfeld MG, Glass CK (2001) Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem 276(40):36865-36868. doi:10.1074/jbc.R100041200R100041200
90. Roth A, Looser R, Kaufmann M, Meyer UA (2008) Sterol regulatory element binding protein 1 interacts with pregnane X receptor and constitutive androstane receptor and represses their target genes. Pharmacogenet Genomics 18(4):325-337. doi:10.1097/FPC. 0b013e3282f706e0 (Pubitemid 351367526)
91. Ruan X, Guan Y (2009) Metabolic syndrome and chronic kidney disease. J Diabetes 1(4):236-245. doi:10.1111/j.1753-0407. 2009.00042.x
92. Ruan XZ, Moorhead JF, Fernando R, Wheeler DC, Powis SH, Varghese Z (2003) PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J Am Soc Nephrol 14(3):593-600 (Pubitemid 36246002)
93. Ruan XZ, Varghese Z, Powis SH, Moorhead JF (2005) Nuclear receptors and their coregulators in kidney. Kidney Int 68(6): 2444-2461. doi:10.1111/j.1523- 1755.2005.00721.x (Pubitemid 43250992)
94. Ruan X, Zheng F, Guan Y (2008) PPARs and the kidney in metabolic syndrome. Am J Physiol Renal Physiol 294(5):F1032-F1047. doi:10.1152/ajprenal. 00152.2007
95. Rutkowski P, Klassen A, Sebekova K, Bahner U, Heidland A (2006) Renal disease in obesity: The need for greater attention. J Ren Nutr 16(3):216-223. doi:10.1053/j.jrn.2006.04.017 (Pubitemid 43975009)
96. Sarafidis PA, Bakris GL (2006) Protection of the kidney by thiazolidinediones: An assessment from bench to bedside. Kidney Int 70(7):1223-1233. doi:10.1038/sj.ki.5001620 (Pubitemid 44435173)
97. Satoh N, Naruse M, Usui T, Tagami T, Suganami T, Yamada K, Kuzuya H, Shimatsu A, Ogawa Y (2004) Leptin-to-adiponectin ratio as a potential atherogenic index in obese type 2 diabetic patients. Diabetes Care 27(10):2488-2490 (Pubitemid 39281406)
98. Schoonjans K, Staels B, Auwerx J (1996) Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37(5):907-925 (Pubitemid 26182326)
99. Schultz JR, Tu H, LukA,Repa JJ,Medina JC,LiL, Schwendner S,Wang S, Thoolen M,Mangelsdorf DJ, Lustig KD, Shan B (2000) Role of LXRs in control of lipogenesis. Genes Dev 14(22):2831-2838
100. Seedorf U, Aberle J (2007) Emerging roles of PPARdelta in metabolism. Biochim Biophys Acta 1771(9):1125-1131. doi: 10.1016/j.bbalip.2007.04.017
101. Sonoda J, Chong LW, Downes M, Barish GD, Coulter S, Liddle C, Lee CH, Evans RM (2005) Pregnane X receptor prevents hepatorenal toxicity from cholesterol metabolites. Proc Natl Acad Sci USA 102(6):2198-2203. doi:10.1073/pnas.0409481102 (Pubitemid 40262035)
102. Sonoda J, Pei L, Evans RM (2008) Nuclear receptors: Decoding metabolic disease. FEBS Lett 582(1):2-9. doi:10.1016/j.febslet. 2007.11.016 (Pubitemid 350297241)
103. Steffensen KR, Gustafsson JA (2004) Putative metabolic effects of the liver X receptor (LXR). Diabetes 53(Suppl 1):S36-S42 (Pubitemid 38168691)
104. Streetz KL, Wustefeld T, Klein C, Manns MP, Trautwein C (2001) Mediators of inflammation and acute phase response in the liver. Cell Mol Biol (Noisy-le-grand) 47(4):661-673
105. Sugden MC, Bulmer K, Gibbons GF, Holness MJ (2001) Role of peroxisome proliferator-activated receptor-alpha in the mechanism underlying changes in renal pyruvate dehydrogenase kinase isoform 4 protein expression in starvation and after refeeding. Arch Biochem Biophys 395(2):246-252. doi:10.1006/abbi.2001. 2586S0003-9861(01)92586-X (Pubitemid 33078260)
106. Takahashi S, Tanaka T, Kodama T, Sakai J (2006) Peroxisome proliferator-activated receptor delta (PPARdelta), a novel target site for drug discovery in metabolic syndrome. Pharmacol Res 53(6):501-507. doi:10.1016/j.phrs.2006.03.019 (Pubitemid 43767554)
107. Tontonoz P, Mangelsdorf DJ (2003) Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 17(6):985-993. doi:10.1210/me.2003- 0061me.2003-0061 (Pubitemid 36683707)
108. Tovar-Palacio C, Tovar AR, Torres N, Cruz C, Hernandez-Pando R, Salas-Garrido G, Pedraza-Chaverri J, Correa-Rotter R (2011) Proinflammatory gene expression and renal lipogenesis are modulated by dietary protein content in obese Zucker fa/fa rats. Am J Physiol Renal Physiol 300(1):F263-F271. doi:10.1152/ ajprenal.00171.2010
109. Ulven SM, Dalen KT, Gustafsson JA, Nebb HI (2005) LXR is crucial in lipid metabolism. Prostaglandins Leukot Essent Fatty Acids 73(1):59-63. doi:10.1016/j.plefa.2005.04.009 (Pubitemid 40826929)
110. Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, Tontonoz P (2000) Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci USA 97(22):12097-12102. doi:10.1073/pnas.2003 67697200367697
111. Wagner M, Zollner G, Trauner M (2011) Nuclear receptors in liver disease. Hepatology 53(3):1023-1034. doi:10.1002/hep.24148
112. Wahba IM, Mak RH (2007) Obesity and obesity-initiated metabolic syndrome: Mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2(3):550-562. doi:10.2215/CJN.04071206
113. Wang H, Chen J, Hollister K, Sowers LC, Forman BM (1999) Endogenous bile acids are ligands for the nuclear receptor FXR/ BAR. Mol Cell 3(5):543-553 (Pubitemid 29268438)
114. Wang YD, Chen WD, Moore DD, Huang W (2008) FXR: A metabolic regulator and cell protector. Cell Res 18(11):1087-1095. doi: 10.1038/cr.2008.289
115. Wang XX, Jiang T, Shen Y, Adorini L, Pruzanski M, Gonzalez FJ, Scherzer P, Lewis L, Miyazaki-Anzai S, Levi M (2009) The farnesoid X receptor modulates renal lipid metabolism and dietinduced renal inflammation, fibrosis, and proteinuria. Am J Physiol Renal Physiol 297(6):F1587-F1596. doi:10.1152/ ajprenal.00404.2009
116. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, Moore DD, Auwerx J (2004) Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 113(10):1408-1418. doi:10.1172/ JCI21025 (Pubitemid 39071696)
117. Wilens SL, Elster SK (1950) The role of lipid deposition in renal arteriolar sclerosis. Am J Med Sci 219(2):183-196 (illust)
118. Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ (1995) LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev 9(9):1033-1045
119. Wu J, Zhang Y, Wang N, Davis L, Yang G, Wang X, Zhu Y, Breyer MD, Guan Y (2004) Liver X receptor-alpha mediates cholesterol efflux in glomerular mesangial cells. Am J Physiol Renal Physiol 287(5):F886-F895. doi:10.1152/ajprenal.00123.2004 (Pubitemid 39391085)
120. Yang T, Michele DE, Park J, Smart AM, Lin Z, Brosius FC 3rd, Schnermann JB, Briggs JP (1999) Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol 277(6 Pt 2):F966-F973 (Pubitemid 30046072)
121. Yang HC, Ma LJ, Ma J, Fogo AB (2006) Peroxisome proliferatoractivated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int 69(10):1756-1764. doi: 10.1038/sj.ki.5000336 (Pubitemid 43739202)
122. Yano M, Matsumura T, Senokuchi T, Ishii N, Murata Y, Taketa K, Motoshima H, Taguchi T, Sonoda K, Kukidome D, Takuwa Y, Kawada T, Brownlee M, Nishikawa T, Araki E (2007) Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res 100(10):1442-1451. doi: 10.1161/01.RES.0000268411.49545.9c (Pubitemid 46834756)
123. Zambon A, Gervois P, Pauletto P, Fruchart JC, Staels B (2006) Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: Clinical and experimental evidence. Arteriosc Thromb Vasc Biol 26(5):977-986. doi:10.1161/01.ATV.0000204327.96431.9a (Pubitemid 43732101)
124. Zhang H, LeCulyse E, Liu L, Hu M, Matoney L, Zhu W, Yan B (1999) Rat pregnane X receptor: Molecular cloning, tissue distribution, and xenobiotic regulation. Arch Biochem Biophys 368(1):14-22. doi:10.1006/abbi.1999.1307 (Pubitemid 29372299)
125. Zhang Y, Castellani LW, Sinal CJ, Gonzalez FJ, Edwards PA (2004) Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev 18(2):157-169. doi:10.1101/gad.1138104 (Pubitemid 38141784)
126. Zheng F, Fornoni A, Elliot SJ, Guan Y, Breyer MD, Striker LJ, Striker GE (2002) Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. Am J Physiol Renal Physiol 282(4):F639-F648. doi:10.1152/ajprenal. 00189.2001 (Pubitemid 34654511)
127. Zhou C, Tabb MM, Nelson EL, Grun F, Verma S, Sadatrafiei A, Lin M, Mallick S, Forman BM, Thummel KE, Blumberg B (2006) Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J Clin Invest 116(8):2280-2289. doi:10.1172/ JCI26283 (Pubitemid 44162338)